FDA Greenlights Sotyktu to Treat Active Psoriatic Arthritis in Adults
The U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib), developed by Bristol Myers Squibb, for the treatment of adults living with Psoriatic Arthritis (PsA). This approval introduces a new oral treatment option for patients suffering from this chronic autoimmune disease, which affects both the joints and skin.
The decision by the U.S. Food and Drug Administration was based on results from two pivotal Phase 3 clinical trials—POETYK PsA-1 and POETYK PsA-2—that demonstrated the drug’s ability to significantly improve disease symptoms compared with placebo. Sotyktu is administered as a once-daily oral tablet and represents the first and only approved tyrosine kinase 2 (TYK2) inhibitor specifically indicated for psoriatic arthritis.
A New Treatment Option for Psoriatic Arthritis
Psoriatic arthritis is a progressive inflammatory condition that often develops in people who have Psoriasis, a skin disorder characterized by red, scaly patches. The disease causes swelling, stiffness, and pain in the joints and can also affect tendons and ligaments. Over time, untreated inflammation may lead to joint damage and reduced mobility.
Because of its complex nature, patients frequently require therapies that address both the joint inflammation and the skin symptoms associated with the disease. The approval of Sotyktu provides clinicians with a new oral therapy designed to target the immune pathways that drive psoriatic disease.
Al Reba, senior vice president of Cardiovascular and Immunology Commercialization at Bristol Myers Squibb, described the approval as an important milestone. According to the company, the introduction of Sotyktu offers a differentiated therapeutic approach and expands treatment choices for people living with active psoriatic arthritis.
He emphasized that the approval reinforces the medication’s potential role in addressing both skin and joint symptoms in psoriatic disease. In addition, the company continues to explore the drug’s potential in other immune-mediated conditions that currently have limited treatment options.
Clinical Trials Supporting FDA Approval
The FDA’s decision was supported by positive data from two large Phase 3 clinical trials known as POETYK PsA-1 and POETYK PsA-2. These studies evaluated the safety and effectiveness of 6 mg of Sotyktu taken once daily in adults with active psoriatic arthritis.
Both trials compared patients receiving Sotyktu with those receiving a placebo. Researchers measured improvements in disease activity using the American College of Rheumatology (ACR) response criteria, which track reductions in joint swelling, tenderness, and other symptoms.
The primary endpoint for both studies was the ACR20 response, meaning at least a 20% improvement in symptoms.
At Week 16, results showed that:
- 54% of patients receiving Sotyktu in the PsA-1 trial achieved an ACR20 response, compared with 34% of patients receiving placebo.
- In the PsA-2 trial, 54% of patients treated with Sotyktu reached the same benchmark, compared with 39% of placebo participants.
These findings demonstrated statistically significant improvements in disease activity for patients receiving the drug.
Additional Measures of Improvement
Beyond the primary endpoint, the trials also evaluated several additional indicators of treatment effectiveness.
These included:
- ACR50 response: at least 50% improvement in symptoms
- ACR70 response: at least 70% improvement
- Minimal Disease Activity (MDA) response
In both trials, patients treated with Sotyktu achieved higher response rates compared with placebo across these measures.
For example, the ACR50 response rate reached approximately 24% in PsA-1 and 29% in PsA-2 among patients receiving Sotyktu, while the placebo groups reported lower rates. Similarly, ACR70 responses—representing substantial symptom improvement—were more common among Sotyktu-treated participants.
Minimal Disease Activity responses were also significantly higher in patients receiving the drug. Achieving minimal disease activity typically requires improvement across several factors, including joint counts, pain levels, skin involvement, physical functioning, and inflammation markers.
Together, these results indicate that Sotyktu can meaningfully reduce disease activity and improve overall health status for patients with active psoriatic arthritis.
Improvements in Quality of Life
Beyond physical symptom reduction, researchers also evaluated the impact of treatment on patients’ quality of life.
Clinical trials measured health-related quality of life using the 36-Item Short Form Health Survey (SF-36). This widely used assessment measures physical functioning, pain, general health, and other aspects of well-being.
Patients treated with Sotyktu experienced improvements in the Physical Component Summary (PCS) score of the SF-36 compared with those receiving placebo after 16 weeks of treatment.
Improvements were also observed across several physical health domains, including:
- Physical functioning
- Role limitations due to physical health
- Bodily pain
- General health perception
According to Philip J. Mease, MD, director of rheumatology research at Providence Swedish Medical Center and clinical professor at the University of Washington School of Medicine, these improvements are significant for people living with psoriatic arthritis.
He explained that patients with the disease often struggle with persistent pain, reduced mobility, and fatigue. These symptoms can interfere with daily activities, employment, and overall quality of life. Therefore, therapies that provide effective symptom control while improving physical function are particularly valuable.
Safety Profile of Sotyktu
The overall safety findings observed in the psoriatic arthritis studies were generally consistent with the safety profile already established for the drug in patients with plaque psoriasis.
Common side effects reported in clinical trials included:
- Upper respiratory infections
- Increased blood creatine phosphokinase (CPK) levels
- Herpes simplex infections
- Mouth ulcers
- Folliculitis
- Acne
Although these adverse reactions were generally manageable, the medication carries several warnings and precautions.
Potential risks associated with Sotyktu include:
- Hypersensitivity reactions
- Serious infections
- Tuberculosis
- Certain cancers, including lymphomas
- Rhabdomyolysis and elevated muscle enzymes
- Laboratory abnormalities
- Considerations related to immunizations
Because the drug targets immune signaling pathways, clinicians must monitor patients carefully for signs of infection or other complications.
Support from the Arthritis Community
Patient advocacy organizations have also welcomed the approval of this new treatment option.
Steven Taylor, president and chief executive officer of the Arthritis Foundation, noted that people living with psoriatic arthritis have long awaited additional oral therapies that can effectively address both joint and skin symptoms.
He emphasized that the disease can be debilitating for many individuals, affecting mobility, productivity, and overall quality of life. The introduction of a new oral therapy may provide patients and physicians with greater flexibility when selecting treatments.
Previous Approvals and Ongoing Research
This is not the first regulatory approval for Sotyktu. The FDA initially approved the medication in 2022 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Since that time, regulatory authorities in multiple countries have also approved the drug for psoriasis treatment.
The medication now has approximately five years of clinical data supporting its efficacy and safety in patients with moderate-to-severe psoriasis. However, Sotyktu is not recommended for use alongside certain potent immunosuppressive drugs in that population.
The latest approval expands the drug’s use into psoriatic arthritis, further strengthening its role in the treatment of immune-mediated inflammatory diseases.
Commitment to Addressing Unmet Medical Needs
Bristol Myers Squibb continues to investigate the therapeutic potential of Sotyktu in additional conditions involving immune system dysregulation.
According to the company, the approval for psoriatic arthritis represents an important step in its broader mission to develop innovative therapies that address unmet medical needs.
By targeting the TYK2 pathway—a key signaling component involved in inflammatory and immune responses—Sotyktu may offer a novel approach for treating several autoimmune diseases.
Looking Ahead
With the FDA approval now in place, healthcare providers in the United States can begin prescribing Sotyktu to eligible adults with active psoriatic arthritis.
The new therapy provides an additional treatment option for patients who require effective control of both joint inflammation and skin symptoms. As researchers continue studying TYK2 inhibition and its potential applications, Sotyktu may play an increasingly important role in the evolving treatment landscape for autoimmune diseases.
For patients living with psoriatic arthritis, the availability of this new oral medication represents a meaningful step forward in expanding treatment choices and improving disease management.
